Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.

Future oncology (London, England) - 1 Nov 2015

Remon Jordi, Planchard David

Abstract excerpt

Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. T790M mutation is the cause of this resistance in approximately 60% of cases. AZD9291 is an oral, irreversible, mutant-selective EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) developed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Clinical Trials, Phase III as Topic

Share to Drug Evaluation, Preclinical

Share to Neoplasm Recurrence, Local

Share to Retreatment

Source

Identifiers

PMID: 26450446
DOI: 10.2217/fon.15.250

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.PMID 26450446Read ↗

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.Semantic proximity Read ↗

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.Semantic proximity Read ↗

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.Semantic proximity Read ↗

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.Semantic proximity Read ↗

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.Semantic proximity Read ↗

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studiesSemantic proximity Read ↗

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.Semantic proximity Read ↗

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.Semantic proximity Read ↗

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.Semantic proximity Read ↗

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.